Mallinckrodt announced publication of a retrospective analysis assessing the efficacy of H.P. Acthar Gel (repository corticotropin injection) in kidney transplant...
Mallinckrodt is reporting interim data at the midway point of enrollment in the ongoing Phase IV, multicenter study assessing the...
Mallinckrodt Plc is reporting that all primary and secondary outcome measures were met in its Phase IV, multicenter study assessing...
Mallinckrodt plc and Questcor Pharmaceuticals, Inc. have announced that they have entered into a definitive merger agreement under which Mallinckrodt...
Mallinckrodt plc announced findings from a large retrospective study of Acthar Gel (repository corticotropin injection) in the treatment of the...
Mallinckrodt plc announced positive top-line findings from its observational registry to assess treatment patterns and response to Acthar Gel (repository...
Mallinckrodt Plc, confirmed enrollment of the first patient in the company's Phase IV, multi-center, multiple-dose, open-label study to assess the...